Business
CorMedix Inc. to Participate in the 24th Annual Needham Virtual Healthcare Conference
BERKELEY HEIGHTS, N.J., April 02, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing
About this update from Cormedix Inc.
BERKELEY HEIGHTS, N.J. , April 02, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that management will be participating in the 24th Annual Needham Virtual Healthcare Conference , taking place virtually on April 7-10, 2025 . 24 th Annual Needham Virtual Healthcare Conference Date: Tuesday, April 8, 2025 Time: 2:15p.m. EDT Format: Fireside Chat Webcast: Link About CorMedix CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product DefenCath® (taurolidine and heparin) which was approved by the FDA on November 15, 2023 . CorMedix commercially launched DefenCath in inpatient settings in April 2024 and in outpatient settings in July 2024 . CorMedix is commencing clinical studies in adult Total Parenteral Nutrition (TPN) patients and pediatric hemodialysis (HD) patient populations in 2025 and also intends to develop DefenCath as a catheter lock solution for use in other therapeutic areas. For more information visit: www.cormedix.com . Investor Contact: Dan Ferry Managing Director LifeSci Advisors [email protected] (617) 430-7576 Source: CorMedix, Inc.